Price movement over the last 24 hours
AdaptHealth Corp vs S&P Global Inc — how do they compare? AdaptHealth Corp trades at $10.04 (market cap $1.38B), while S&P Global Inc trades at $433.52 (market cap $131.26B). The key difference: S&P Global Inc is far larger — about 95.1× AdaptHealth Corp's market cap, and S&P Global Inc pays a 0.87% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | SPGI | |
|---|---|---|
Market Cap | $1.38B | $131.26B |
Sector | Health | Financials |
52-Week High | $13.38 | $534.79 |
52-Week Low | $8.68 | $370.42 |
Enterprise Value | $3.33B | $143.23B |
Dividend Yield | — | 0.87% |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
S&P Global (SPGI) trades at $443.46, up 0.81% with strong bullish momentum. The stock shows robust fundamentals with 29.15% net margin and consistent earnings beats in three of the last four quarters. Recent completion of Mobility Global spinoff and AI-driven market intelligence initiatives position the company for growth. Technical indicators show bullish moving averages while RSI suggests potential overbought conditions near-term.
Outlook remains positive with 85.7% analyst buy ratings and $533.50 consensus target implying 20% upside. Key risks include interest rate sensitivity in credit rating segment and execution of AI transformation. The company's subscription-based revenue model and market data dominance provide stable cash flow foundation for long-term growth.
Trailing returns across standard periods
Latest headlines on both assets
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →